Hikma decides injectables drug business a prize to hold onto

Eric Palmer When Mylan agreed to pay $ 1.6 billion to nab Strides Arcolab's sterile injectables drug business, the competitors it bested were thought to be sniffing around elsewhere ...

Abbott aids biotech Epizyme in matching epigenetic drug with cancer patients

Ryan McBride Abbott ($ ABT) plans to develop a companion diagnostic test for an experimental leukemia drug from the biotech startup Epizyme. The agreement follows the start of a Phase ...

Cipla steamrolls into Enbrel market with biosimilar of Amgen drug

Tracy Staton While the FDA continues its slow-motion release of new guidelines for producing biosimilars in the U.S., India's Cipla has stepped up with a knockoff of the rheumatoid ...

Vivus clears one of many hurdles for new weight drug

Ryan McBride The FDA has agreed to take down one of the big hurdles hampering U.S. sales of Vivus' newly approved weight drug Qsymia, but plenty more remain. Vivus ($ VVUS) says ...

Bristol-Myers forges discovery pact with rising RNA drug player

Ryan McBride Santaris Pharma has found another major pharma partner for its RNA drug platform. Bristol-Myers Squibb ($ BMY) has forked over $ 10 million initially and promised much ...

FDA denies inhaled migraine drug from Allergan

Ryan McBride Allergan ($ AGN) lost the latest bid for FDA approval of an inhaled version of the long-used drug dihydroergotamin for acute migraines. The U.S. regulator handed Allergan, ...

Eli Lilly scores upbeat PhIII data for GLP1 drug in busy diabetes market

Ryan McBride Eli Lilly ($ LLY) has added to a body of positive Phase III data for its once-weekly GLP-1 candidate dulaglutide, with two more late-stage studies that have met their ...

Roche, billionaire-backed biotech partner on hep C drug in China

Ryan McBride Roche ($ RHHBY) and the biotech startup Ascletis have joined forces to advance Roche's experimental drug danoprevir for hepatitis C virus in the Chinese market. As ...

Sanofi CEO fires surprise torpedo at Alzheimer’s drug research

Ryan McBride Count Sanofi ($ SNY) out of the wild chase to develop Alzheimer's drugs, at least while the best line of attack against the memory-robbing disease remains unclear. ...

Pharma reps aren’t talking about drug risks, study finds

Tracy Staton Doctors aren't getting the skinny on drug side effects from pharma reps, a new study finds. Even the most serious risks are often overlooked, the survey found. And ...

President’s budget takes a big bite out of Medicare drug spending

Tracy Staton Expect plenty of teeth-gnashing in the pharma industry over the next several weeks. President Obama's budget proposal not only proposes accelerated discounts for Medicare ...
Page 45 of 45« First...102030...4142434445
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS